Login   |  Users Online: 2051 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Search Article 
  
Advanced search 
   Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts
RESEARCH ARTICLE
Year : 2009  |  Volume : 30  |  Issue : 4  |  Page : 409-414

Role of Manahshiladi Anjana and Jeevantyadi Ghrita on Linganasha - Cataract


1 Reader, Dept. of Shalakya, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, India
2 Formerly Professor & Head, Dept. of Shalakya, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, India
3 Formerly Professor, Dept. of Shalakya, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, India
4 Ph.D. Scholar, Dept. of Shalakya, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, India

Correspondence Address:
Manjusha Rajagopala
Reader, Dept. of Shalakya, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Cataract - Linganasha is defined as loss of transparency of lens developing as a result of altered physiological process within its substance. The disease Linganasha is mainly due to vitiation of Kapha Dosha. According to the 1992 the status report of DGHS, Govt. of India, Cataract alone is responsible for 81% cases of blindness. While the problem of blindness is global, its magnitude is much higher in India. Of the estimated 45 million, India alone has 12 million blind people. In this study patients were selected from the O.P.D. and I.P.D. of Shalya - Shalakya dept and randomly divided into three groups i.e. in Group-A Manahshiladi Anjana (Local application), Group-B Jeevantyadi Ghrita (Internal use) and in Group - C Rasanjana Netra Bindu and Godanti Cap. 500 mg. (Control group) were administered for 6 months. In this study total 195 patients were registered and 99 patients completed the course of treatment. Maximum relief was observed on Polyopia / Diplopia in Group A and B, whereas increase in the clinical features was found in Group C.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed880    
    Printed65    
    Emailed0    
    PDF Downloaded331    
    Comments [Add]    

Recommend this journal